CY1122160T1 - Μορφες δοσολογιας δραστικων ουσιων για χορηγηση απο το στομα - Google Patents
Μορφες δοσολογιας δραστικων ουσιων για χορηγηση απο το στομαInfo
- Publication number
- CY1122160T1 CY1122160T1 CY20191100901T CY191100901T CY1122160T1 CY 1122160 T1 CY1122160 T1 CY 1122160T1 CY 20191100901 T CY20191100901 T CY 20191100901T CY 191100901 T CY191100901 T CY 191100901T CY 1122160 T1 CY1122160 T1 CY 1122160T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dosage forms
- oral administration
- active substances
- active ingredients
- microgranules
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Σε μία πτυχή, η παρούσα εφεύρεση αναφέρεται σε ένα σύστημα για την τροποποιημένη αποδέσμευση ενός ή περισσοτέρων δραστικών συστατικών, το οποίο περιλαμβάνει μία μήτρα πολυμερούς που βασίζεται σε υαλουρονικό οξύ με μοριακό βάρος που κυμαίνεται από 100 έως 100.000 Daltons και ένα μη ιονικό πολυμερές το οποίο σχηματίζει πηκτή σε επαφή με νερό, στο οποίο διασπείρονται ένα ή περισσότερα δραστικά συστατικά, προαιρετικά σε μορφή μικρόκοκκων ή μικροκαψουλών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000682A ITMI20130682A1 (it) | 2013-04-24 | 2013-04-24 | Forme di dosaggio per la somministrazione orale di sostanze attive |
| PCT/IB2014/060892 WO2014174430A1 (en) | 2013-04-24 | 2014-04-22 | Dosage forms for oral administration of active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122160T1 true CY1122160T1 (el) | 2020-11-25 |
Family
ID=48748359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100901T CY1122160T1 (el) | 2013-04-24 | 2019-08-22 | Μορφες δοσολογιας δραστικων ουσιων για χορηγηση απο το στομα |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160081935A1 (el) |
| EP (1) | EP2988782B1 (el) |
| CA (1) | CA2910354C (el) |
| CY (1) | CY1122160T1 (el) |
| DK (1) | DK2988782T3 (el) |
| ES (1) | ES2741501T3 (el) |
| HR (1) | HRP20191493T1 (el) |
| HU (1) | HUE044668T2 (el) |
| IT (1) | ITMI20130682A1 (el) |
| LT (1) | LT2988782T (el) |
| PL (1) | PL2988782T3 (el) |
| PT (1) | PT2988782T (el) |
| RS (1) | RS59133B1 (el) |
| SI (1) | SI2988782T1 (el) |
| TR (1) | TR201910708T4 (el) |
| WO (1) | WO2014174430A1 (el) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319510B1 (en) * | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| JP2004525110A (ja) * | 2001-02-16 | 2004-08-19 | 清水製薬株式会社 | ムコ多糖類製剤およびその製造法 |
| US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
| TW200524959A (en) * | 2003-09-08 | 2005-08-01 | Chugai Pharmaceutical Co Ltd | Hyaluronic acid modification product and drug carrier therefrom |
| WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
| ITMI20050262A1 (it) * | 2005-02-21 | 2006-08-22 | Carlo Ghisalberti | Sostanze composizioni e metodi di trattamento dell'alopecia |
| US20100098794A1 (en) * | 2008-10-17 | 2010-04-22 | Armand Gerard | Topical anti-wrinkle and anti-aging moisturizing cream |
-
2013
- 2013-04-24 IT IT000682A patent/ITMI20130682A1/it unknown
-
2014
- 2014-04-22 ES ES14731011T patent/ES2741501T3/es active Active
- 2014-04-22 US US14/786,496 patent/US20160081935A1/en not_active Abandoned
- 2014-04-22 CA CA2910354A patent/CA2910354C/en active Active
- 2014-04-22 SI SI201431283T patent/SI2988782T1/sl unknown
- 2014-04-22 PL PL14731011T patent/PL2988782T3/pl unknown
- 2014-04-22 TR TR2019/10708T patent/TR201910708T4/tr unknown
- 2014-04-22 HU HUE14731011 patent/HUE044668T2/hu unknown
- 2014-04-22 DK DK14731011.4T patent/DK2988782T3/da active
- 2014-04-22 RS RS20191015A patent/RS59133B1/sr unknown
- 2014-04-22 LT LTEP14731011.4T patent/LT2988782T/lt unknown
- 2014-04-22 WO PCT/IB2014/060892 patent/WO2014174430A1/en active Application Filing
- 2014-04-22 PT PT14731011T patent/PT2988782T/pt unknown
- 2014-04-22 EP EP14731011.4A patent/EP2988782B1/en active Active
-
2019
- 2019-08-19 HR HRP20191493 patent/HRP20191493T1/hr unknown
- 2019-08-22 CY CY20191100901T patent/CY1122160T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160081935A1 (en) | 2016-03-24 |
| ES2741501T3 (es) | 2020-02-11 |
| TR201910708T4 (tr) | 2019-08-21 |
| PL2988782T3 (pl) | 2019-12-31 |
| ITMI20130682A1 (it) | 2014-10-25 |
| CA2910354C (en) | 2021-04-27 |
| CA2910354A1 (en) | 2014-10-30 |
| LT2988782T (lt) | 2019-08-12 |
| RS59133B1 (sr) | 2019-09-30 |
| HUE044668T2 (hu) | 2019-11-28 |
| WO2014174430A1 (en) | 2014-10-30 |
| SI2988782T1 (sl) | 2019-09-30 |
| PT2988782T (pt) | 2019-09-10 |
| EP2988782A1 (en) | 2016-03-02 |
| DK2988782T3 (da) | 2019-07-29 |
| HRP20191493T1 (hr) | 2019-11-15 |
| EP2988782B1 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119312T1 (el) | Εγκεκλεισμενες ανθεκτικες εναντι παραβιασης μορφες δοσολογιας ελεγχομενης αποδεσμευσης | |
| CY1122480T1 (el) | Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας | |
| CY1123735T1 (el) | Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης | |
| CY1119166T1 (el) | Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι | |
| CY1122796T1 (el) | Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων | |
| CY1124380T1 (el) | Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης | |
| CY1121852T1 (el) | Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου | |
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| MX363844B (es) | Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional. | |
| BR112016008409A2 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
| BR112018002342A2 (pt) | polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos | |
| MA39362A1 (fr) | Compositions stables d'iode non complexé et procédés d'utilisation. | |
| CY1119930T1 (el) | Λευκολεκτινες και χρησεις αυτων | |
| UY35442A (es) | COMPOSICIONES DE ARNi DEL COMPONENTE DEL COMPLEMENTO C5 Y MÉTODOS PARA SU USO | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| BR112015015858A2 (pt) | composição farmacêutica de solução sólida | |
| DOP2015000058A (es) | Derivados tricíclicos de quinolinas y de quinoxalinas | |
| CY1117654T1 (el) | Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης | |
| BR112015015864A2 (pt) | composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica | |
| UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| CY1117300T1 (el) | Νεα ενισχυμενη συσκευασια με φυσαλιδες | |
| MX2016007534A (es) | Composicion de gel de acido hialuronico que tiene durabilidad. | |
| BR112015024271A2 (pt) | sistema de fornecimento transdérmico | |
| CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης |